Example collocations logo

Vaccines in sentence

693 examples of Vaccines in a sentence

Vaccines for all three of these dread diseases are within scientific reach, but will requires some billions of dollars to bring through the research and development stages to actual use.
After all, the $10 billion or so in costs of bombing Kosovo this spring could probably have paid for the needed scientific work over the next few years on all three vaccines!
Rotary took on the challenge of getting vaccines to the poor, in regions with weak or non-existent public health systems.
Red Cross chapters across Africa, in partnership with other organizations, are now distributing bed nets free of charge to impoverished families, in the same way that Rotary has been distributing polio vaccines.
Recently, the US Senate approved spending $8 billion to stockpile vaccines and other drugs to help prevent a possible bird flu epidemic.
Other governments have already spent tens of millions on vaccines and other preventive measures.
Ironically, many deaths would be preventable by existing vaccines (such as for measles), but the populations are often too poor to have access to even basic public health.
The continued targeting of such brave workers is posing a severe challenge to these countries’ public-health communities and their collective ambition to reach every child with lifesaving vaccines.
Each year, these vaccines alone saved more people than world peace would have saved in the twentieth century.
Health conditions have worsened as well, owing to nutritional deficiencies and the government’s decision not to supply infant formula, standard vaccines against infectious diseases, medicines for AIDS, transplant, cancer, and dialysis patients, and general hospital supplies.
On more than 20 occasions, Trump has tweeted about a potential link between vaccines and autism.
By making vaccines available through national immunization programs, governments can protect all children from the diseases that are most likely to harm or kill them.
These diseases often lack effective preventative or curative vaccines or medicines, or the treatments that are available are too costly for the impoverished populations.
$60 billion of foreign aid per year could stimulate a lot of new medicines, vaccines, hybrid seeds, and the like.
Pay-or-Play CapitalismLONDON – When I led the British government’s Review on Antimicrobial Resistance (AMR) from 2014 to 2016, we suggested various ways to fund a market-entry reward for drug makers that develop new antibiotics and vaccines.
Given that there are no vaccines or drug treatments for illnesses like dengue fever and West Nile virus, and that treatments for diseases like malaria are difficult to access in many at-risk areas, more effective mechanisms for controlling mosquito populations are desperately needed.
It encompasses research initiatives and global public goods such as vaccines and emergency-preparedness programs for epidemic outbreaks.
In the absence of effective vaccines or new anti-malarial drugs – and the funding and infrastructure to deliver them – this decision is tantamount to mass murder, a triumph of radical environmental politics over public health.
In fact, delivering basic vaccines is still one of our top priorities.
As I look ahead to 2014, I am more optimistic than ever about the progress that we can make using the power of vaccines to give all children – wherever they live – a healthy start to life.
We are developing new and better vaccines to protect kids from deadly diseases.
By harnessing the same innovative spirit that transformed emerging markets into manufacturing hubs for everything from cars to computers, these companies have become leaders in supplying the world with high quality, low-cost vaccines.
Serum Institute produces a higher volume of vaccines than any other company in the world and has played a key role in cutting costs and boosting volumes.
We have also seen major emerging countries invest in biomedical technology to supply developing countries with new vaccines.
India’s Department of Biotechnology and Bharat Biotech announced plans this year to release a new vaccine against rotavirus – which kills hundreds of thousands of children – for $1 per dose, significantly cheaper than existing vaccines.
Today, emerging-country manufacturers produce about 50% of vaccines purchased by United Nations agencies for use in the developing world, up from less than 10% in 1997.
A joint partnership with GlaxoSmithKline will produce a six-in-one vaccine protecting children against polio and other infectious diseases; another, with Novartis, will produce two vaccines that will protect millions of people in the developing world from typhoid and paratyphoid fevers.
Despite all of this progress, more must be done to target the 22 million children, mainly in the poorest countries, who do not have access to lifesaving vaccines.
We have the knowhow to produce effective vaccines, make them affordable, and deliver them to the children who need them.
That is not just because vaccines are not readily available; it is also because women in these countries have limited access to screening and treatment.
BackNext